IDT Australia Limited provided earnings guidance for the second half of 2013. The Board of the company announced that it has received advice from a North American Pharmaceutical client that as a result of further FDA regulatory requirements there will be delays in the timing of its large development project till fiscal year 2014. Consequently, as a result of this delay, the Board expects that the financial result for second half of fiscal year 2013 will be similar to the financial result for first half of fiscal year 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.125 AUD | +8.70% | +25.00% | +13.64% |
06-04 | IDT Australia Raising About AU$7 Million Via Entitlement Offer; Shares Up 10% | MT |
05-06 | IDT Australia Secures Victorian Government Funding for Cancer Medication Production Facility | MT |
1st Jan change | Capi. | |
---|---|---|
+13.64% | 28.92M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- IDT Stock
- News IDT Australia Limited
- IDT Australia Limited Provides Earnings Guidance for the Second Half of 2013